SEC Filing | Biogen

View:

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hasnain Faheem

(Last)

(First)

(Middle)

14 CAMBRIDGE CENTER

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN IDEC INC [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP, Oncology SBU

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2006

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right-to-buy)⁽¹⁾	$44.24	02/06/2006		A		40,900		⁽²⁾	02/05/2016	Common Stock	40,900	⁽¹⁾	40,900	D
Restricted Stock Units	⁽³⁾	02/06/2006		A		16,400		⁽⁴⁾	⁽³⁾	Common Stock	16,400	⁽³⁾	16,400	D

Explanation of Responses:

1. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).

2. The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/06/06.

3. Each restricted stock unit represents a contingent right to receive one share of BIIB common stock.

4. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/06/06.

Remarks:

	by: Kevin M. Foley; for: Faheem Hasnain	02/08/2006
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS




	Know all by these presents, that the undersigned's hereby makes,

constitutes and appoints Benjamin S. Harshbarger, Daniel S. Char, Jo Ann

Taormina and Kevin M. Foley as the undersigned's true and lawful

attorney-in-fact, with full power and authority as hereinafter described
on
behalf of and in the name, place and stead of the undersigned to:



(1)	prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5

(including any amendments thereto) with respect to the securities of
Biogen
Idec Inc., a Delaware corporation (the "Company"), with the United
States
Securities and Exchange Commission, any national securities
exchanges and
the Company, as considered necessary or advisable under
Section 16(a) of
the Securities Exchange Act of 1934 and the rules and
regulations
promulgated thereunder, as amended from time to time (the
"Exchange Act");


(2)	seek or obtain, as the undersigned's
representative and on the
undersigned's behalf, information on
transactions in the Company's
securities from any third party, including
brokers, employee benefit plan
administrators and trustees, and the
undersigned hereby authorizes any such
person to release any such
information to the undersigned and approves and
ratifies any such release
of information; and

(3)	perform any and all
other acts which in
the discretion of such attorney-in-fact are necessary
or desirable for
and on behalf of the undersigned in connection with the
foregoing.


The undersigned acknowledges that:

(1)	this Power of
Attorney
authorizes, but does not require, such attorney-in-fact to act in
their
discretion on information provided to such attorney-in-fact without

independent verification of such information;

(2)	any documents

prepared and/or executed by such attorney-in-fact on behalf of the

undersigned pursuant to this Power of Attorney will be in such form and

will contain such information and disclosure as such attorney-in-fact, in

his or her discretion, deems necessary or desirable;

(3)	neither
the
Company nor such attorney-in-fact assumes (i) any liability for the

undersigned's responsibility to comply with the requirement of the
Exchange
Act, (ii) any liability of the undersigned for any failure to
comply with
such requirements, or (iii) any obligation or liability of
the undersigned
for profit disgorgement under Section 16(b) of the
Exchange Act; and


(4)	this Power of Attorney does not relieve the
undersigned from
responsibility for compliance with the undersigned's
obligations under the
Exchange Act, including without limitation the
reporting requirements under
Section 16 of the Exchange Act.

	The
undersigned hereby gives and
grants the foregoing attorney-in-fact full
power and authority to do and
perform all and every act and thing
whatsoever requisite, necessary or
appropriate to be done in and about
the foregoing matters as fully to all
intents and purposes as the
undersigned might or could do if present,
hereby ratifying all that such
attorney-in-fact of, for and on behalf of
the undersigned, shall lawfully
do or cause to be done by virtue of this
Limited Power of Attorney.


	This Power of Attorney shall remain in
full force and effect until
revoked by the undersigned in a signed writing
delivered to such
attorney-in-fact.

	IN WITNESS WHEREOF, the
undersigned has caused
this Power of Attorney to be executed as of this 8th
day of February,
2006.



				/s/ Faheem
Hasnain

Faheem Hasnain